BACKGROUND: The proportion of patients with advanced chronic kidney disease (CKD) initiating dialysis therapy at a higher glomerular filtration rate (GFR) has increased during the past decade. Recent data suggest that higher GFR may be associated with increased mortality. STUDY DESIGN: A meta-analysis of cohort studies and trials. SETTING & POPULATION: Patients with advanced CKD. SELECTION CRITERIA FOR STUDIES: We performed a systematic literature search in MEDLINE, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, American Society of Nephrology abstracts, and bibliographies of retrieved articles to identify studies reporting on GFR at dialysis therapy initiation and mortality. PREDICTOR: Estimated or calculated GFR at dialysis therapy initiation. OUTCOME: Pooled adjusted hazard ratio (HR) of continuous GFR for all-cause mortality. RESULTS: 16 cohort studies and 1 randomized controlled trial were identified (n = 1,081,116). By meta-analysis restricted to 15 cohorts (n = 1,079,917), higher GFR at dialysis therapy initiation was associated with a higher pooled adjusted HR for all-cause mortality (1.04; 95% CI, 1.03-1.05; P < 0.001). However, there was significant heterogeneity (I(2) = 97%; P < 0.001). The association persisted among the 9 cohorts that adjusted analytically for nutritional covariates (HR, 1.03; 95% CI, 1.02-1.04; P < 0.001; residual I(2) = 97%). The highest mortality risk was observed in hemodialysis cohorts (HR, 1.05; 95% CI, 1.02-1.08; P < 0.001), whereas there was no association between GFR and mortality in peritoneal dialysis cohorts (HR, 1.04; 95% CI, 0.99-1.08, P = 0.1; residual I(2) = 98%). Finally, higher GFR was associated with a lower mortality risk in cohorts that calculated GFR (HR, 0.80; 95% CI, 0.71-0.91; P = 0.003), contrasting with a higher mortality risk in cohorts that estimated GFR (HR, 1.04; 95% CI, 1.03-1.05; P < 0.001; residual I(2) = 97%). LIMITATIONS: Paucity of randomized controlled trials, different methods for determining GFR, and substantial heterogeneity. CONCLUSIONS: Higher estimated rather than calculated GFR at dialysis therapy initiation is associated with a higher mortality risk in patients with advanced CKD, independent of nutritional status. Although there was substantial heterogeneity of effect size estimates across studies, this observation requires further study.
BACKGROUND: The proportion of patients with advanced chronic kidney disease (CKD) initiating dialysis therapy at a higher glomerular filtration rate (GFR) has increased during the past decade. Recent data suggest that higher GFR may be associated with increased mortality. STUDY DESIGN: A meta-analysis of cohort studies and trials. SETTING & POPULATION: Patients with advanced CKD. SELECTION CRITERIA FOR STUDIES: We performed a systematic literature search in MEDLINE, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, American Society of Nephrology abstracts, and bibliographies of retrieved articles to identify studies reporting on GFR at dialysis therapy initiation and mortality. PREDICTOR: Estimated or calculated GFR at dialysis therapy initiation. OUTCOME: Pooled adjusted hazard ratio (HR) of continuous GFR for all-cause mortality. RESULTS: 16 cohort studies and 1 randomized controlled trial were identified (n = 1,081,116). By meta-analysis restricted to 15 cohorts (n = 1,079,917), higher GFR at dialysis therapy initiation was associated with a higher pooled adjusted HR for all-cause mortality (1.04; 95% CI, 1.03-1.05; P < 0.001). However, there was significant heterogeneity (I(2) = 97%; P < 0.001). The association persisted among the 9 cohorts that adjusted analytically for nutritional covariates (HR, 1.03; 95% CI, 1.02-1.04; P < 0.001; residual I(2) = 97%). The highest mortality risk was observed in hemodialysis cohorts (HR, 1.05; 95% CI, 1.02-1.08; P < 0.001), whereas there was no association between GFR and mortality in peritoneal dialysis cohorts (HR, 1.04; 95% CI, 0.99-1.08, P = 0.1; residual I(2) = 98%). Finally, higher GFR was associated with a lower mortality risk in cohorts that calculated GFR (HR, 0.80; 95% CI, 0.71-0.91; P = 0.003), contrasting with a higher mortality risk in cohorts that estimated GFR (HR, 1.04; 95% CI, 1.03-1.05; P < 0.001; residual I(2) = 97%). LIMITATIONS: Paucity of randomized controlled trials, different methods for determining GFR, and substantial heterogeneity. CONCLUSIONS: Higher estimated rather than calculated GFR at dialysis therapy initiation is associated with a higher mortality risk in patients with advanced CKD, independent of nutritional status. Although there was substantial heterogeneity of effect size estimates across studies, this observation requires further study.
Authors: Allan J Collins; Robert N Foley; Charles Herzog; Blanche Chavers; David Gilbertson; Areef Ishani; Bertram Kasiske; Jiannong Liu; Lih-Wen Mau; Marshall McBean; Anne Murray; Wendy St Peter; Haifeng Guo; Sally Gustafson; Qi Li; Shuling Li; Suying Li; Yi Peng; Yang Qiu; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Changchun Wang; Eric Weinhandl; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frederick Dalleska; Frank Daniels; Stephan Dunning; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa Journal: Am J Kidney Dis Date: 2011-01 Impact factor: 8.860
Authors: Waqar H Kazmi; David T Gilbertson; Gregorio T Obrador; Haifeng Guo; Brian J G Pereira; Allan J Collins; Annamaria T Kausz Journal: Am J Kidney Dis Date: 2005-11 Impact factor: 8.860
Authors: Jamie P Traynor; Keith Simpson; Colin C Geddes; Christopher J Deighan; Jonathan G Fox Journal: J Am Soc Nephrol Date: 2002-08 Impact factor: 10.121
Authors: Deidra C Crews; Julia J Scialla; Jiannong Liu; Haifeng Guo; Karen Bandeen-Roche; Patti L Ephraim; Bernard G Jaar; Stephen M Sozio; Dana C Miskulin; Navdeep Tangri; Tariq Shafi; Klemens B Meyer; Albert W Wu; Neil R Powe; L Ebony Boulware Journal: J Am Soc Nephrol Date: 2013-10-24 Impact factor: 10.121
Authors: Muh Geot Wong; Carol A Pollock; Bruce A Cooper; Pauline Branley; John F Collins; Jonathan C Craig; Joan Kesselhut; Grant Luxton; Andrew Pilmore; David C Harris; David W Johnson Journal: Clin J Am Soc Nephrol Date: 2013-10-31 Impact factor: 8.237
Authors: Deidra C Crews; Julia J Scialla; L Ebony Boulware; Sankar D Navaneethan; Joseph V Nally; Xiaobo Liu; Susana Arrigain; Jesse D Schold; Patti L Ephraim; Stacey E Jolly; Stephen M Sozio; Wieneke M Michels; Dana C Miskulin; Navdeep Tangri; Tariq Shafi; Albert W Wu; Karen Bandeen-Roche Journal: Am J Kidney Dis Date: 2014-02-06 Impact factor: 8.860
Authors: Gihad E Nesrallah; Reem A Mustafa; William F Clark; Adam Bass; Lianne Barnieh; Brenda R Hemmelgarn; Scott Klarenbach; Robert R Quinn; Swapnil Hiremath; Pietro Ravani; Manish M Sood; Louise M Moist Journal: CMAJ Date: 2014-02-04 Impact factor: 8.262